Key Points
- DexCom director Mark Foletta sold 4,000 shares on June 15 at an average price of $74.13, totaling about $296,520. The sale reduced his direct holdings by 7.04% and was made under a pre-arranged Rule 10b5-1 trading plan.
- DexCom recently beat earnings and revenue expectations for its latest quarter, reporting $0.56 EPS on $1.19 billion in revenue versus analyst estimates of $0.47 EPS and $1.17 billion in revenue. Revenue rose 15% year over year.
- Wall Street remains mostly bullish on DXCM, with a consensus rating of “Moderate Buy” and an average price target of $84.83. Analysts cited targets ranging from $80 to $90, despite some recent revisions.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 1,700 shares of the company's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company's stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Jon Brown also recently made the following trade(s):
- On Friday, May 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $59.91, for a total value of $101,847.00.
- On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $63.04, for a total value of $107,168.00.
DexCom Price Performance
Shares of DXCM opened at $71.23 on Thursday. The stock has a fifty day moving average price of $66.75 and a 200 day moving average price of $67.82. The company has a market cap of $27.49 billion, a P/E ratio of 30.44, a PEG ratio of 1.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98.
DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company's quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 earnings per share. On average, research analysts forecast that DexCom, Inc. will post 2.58 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Empowered Funds LLC boosted its holdings in shares of DexCom by 71.8% in the first quarter. Empowered Funds LLC now owns 17,623 shares of the medical device company's stock valued at $1,107,000 after acquiring an additional 7,367 shares in the last quarter. Defilade Capital Management L.P. boosted its stake in DexCom by 120.0% during the 1st quarter. Defilade Capital Management L.P. now owns 538,762 shares of the medical device company's stock valued at $33,834,000 after purchasing an additional 293,881 shares in the last quarter. Avidity Partners Management LP bought a new position in DexCom during the 1st quarter valued at $5,652,000. Glenmede Trust Co. NA boosted its stake in DexCom by 36.7% during the 1st quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company's stock valued at $24,790,000 after purchasing an additional 105,928 shares in the last quarter. Finally, Wellington Grp LLC boosted its stake in DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after purchasing an additional 475 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have commented on DXCM shares. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research report on Friday, May 1st. William Blair raised DexCom to a "strong-buy" rating in a report on Friday, May 15th. Mizuho set a $85.00 price objective on DexCom and gave the stock an "outperform" rating in a report on Tuesday, June 9th. Wall Street Zen lowered DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, May 10th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $91.00 price objective on shares of DexCom in a report on Monday, June 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, DexCom has an average rating of "Moderate Buy" and an average price target of $84.83.
Get Our Latest Report on DXCM
DexCom Company Profile
(
Get Free Report)
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
